Attention-deficit hyperactivity disorder. Attention-deficit hyperactivity disorders
Conditions
Interventions
Intervention group: participants have ADHD and receive six weeks of medication with Methylphenidate 0.5 -1mg/kg/day divided into three daily doses (1mg per kg maximum dosage). In this study Methylphe
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
8 Years to 12 Years
Inclusion criteria
Inclusion criteria: ADHD diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Male sex Age 8-12 years IQ more than 90 according to Wechsler Intelligence Scale
Exclusion criteria
Exclusion criteria: Major psychiatric disorders Neurologic disorders Major medical disorders Taking medications that affect the central nervous system substance abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the activity of brain regions related to the undrestanding intentionality. Timepoint: Before, and six weeks after starting the treatment with Methylphenidate. Method of measurement: Fanctional magnetic resonance brain imaging (fMRI). | — |
Secondary
| Measure | Time frame |
|---|---|
| Ability of response inhibition. Timepoint: Before and six weeks after starting the treatment with Methylphenidate. Method of measurement: Stop-Signal task by Cambridge Neuropsychological Test Automated Battery (CANTAB).;Severity of core symptoms of attention deficit-hyperactivity disorder. Timepoint: Before and six weeks after starting the treatment with Methylphenidate. Method of measurement: Conners’ Parent Rating Scale (Questionnaire).;The effects of symptoms on behavior in terms of family, education, social and psychological. Timepoint: Before and six weeks after starting the treatment with Methylphenidate. Method of measurement: Children’s Global Assessment Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehdi Tehrani-Doost
Tehran University of Medical Sciences
Outcome results
None listed